Form 4: ESSA Pharma COO Sells Shares Under 10b5-1 Trading Plan

Peter Virsik, COO of ESSA Pharma Inc., sold 694 common shares at a weighted average price of $7.94 on April 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 5, 2024, Peter Virsik, the Chief Operating Officer of ESSA Pharma Inc., sold 694 common shares of the company.
• The sale was executed at a weighted average price of $7.94 per share.
• This transaction was conducted under a pre-existing 10b5-1 trading plan established on August 31, 2023.
• Following the transaction, Mr. Virsik directly owns 11,940 common shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is part of a pre-arranged trading plan and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Stakeholder Impact

• The sale of shares by a company executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the transaction.

Key Dates